Andrew M. Callos serves as the Executive Vice President and Chief Commercial Officer at Cytokinetics, Incorporated, a biopharmaceutical company focused on developing muscle activators and inhibitors as potential treatments for debilitating diseases. In his role, Callos is responsible for leading the company's commercial strategy and operations, overseeing the development and execution of global commercialization plans for Cytokinetics' innovative pipeline of drug candidates. Prior to joining Cytokinetics, Callos held several leadership positions in the biopharmaceutical industry, accumulating extensive experience in commercial strategy, product launches, and business development. He previously served as Senior Vice President and Business Unit Head at Astellas Pharma, where he played a key role in the successful launch and commercialization of several high-profile products. Before Astellas, Callos held various commercial leadership roles at Amgen, where he contributed to the growth and expansion of the company's oncology and nephrology portfolios. Callos's strategic vision and deep understanding of the biopharmaceutical market have been instrumental in driving Cytokinetics' commercial success. Under his leadership, the company has made significant progress in advancing its clinical programs and preparing for potential product launches. His expertise in building high-performing teams and developing innovative go-to-market strategies has positioned Cytokinetics for long-term growth and success in the competitive biopharmaceutical landscape.